ISRCTN ISRCTN12151923
DOI https://doi.org/10.1186/ISRCTN12151923
Submission date
22/11/2020
Registration date
04/12/2020
Last edited
27/09/2022
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Oral Health
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Background and study aims
Periodontitis, also called gum disease, is a serious gum infection that damages the soft tissue and, without treatment, can destroy the bone that supports your teeth. Periodontitis can cause teeth to loosen or lead to tooth loss.
Some studies have shown that the use of antibiotics can provide some benefits. However, there are no studies that have evaluated how well metronidazole works as an antibiotic in surgical periodontal therapy. Therefore, the objective of our study was to determine whether the use of an antibiotic (metronidazole), as an added treatment to periodontal surgery, provides additional clinical and microbiological benefits, in patients with generalized severe periodontitis.

Who can participate?
Systemically healthy patients of both genders, aged 18 years or older, diagnosed with generalized severe periodontitis.

What does the study involve?
Participants are randomly allocated to receive adjunctive metronidazole or placebo. Clinical variables were recorded at baseline, 6 weeks after subgingival instrumentation, and after 3, 6 and 12 months. Microbiological samples were taken at the initial and final visits and analyzed by multiplex quantitative polymerase chain reaction (qPCR).

What are the possible benefits and risks of participating?
In this study, patients will benefit from non-surgical and surgical periodontal treatment of periodotitis. The treatment is expected to obtain improvements in periodontal clinical parameters such as a decrease in probing depth, gain in the level of clinical attachment, and resolution of inflammation. A greater decrease in bacterias would also be expected in the test group receiving the antibiotics. Although the adverse and unwanted effects associated with the use of systemic antibiotics must be taken into consideration.

Where is the study run from?
Pontificia Universidad Católica Madre y Maestra (Dominican Republic)

When is the study starting and how long is it expected to run for?
April 2014 to May 2019

Who is funding the study?
Pontificia Universidad Católica Madre y Maestra (Dominican Republic)

Who is the main contact?
Dr James R. Collins
jamescollins@pucmm.edu.do

Contact information

Prof James Collins
Scientific

Av Abraham Lincoln esq. Simón Bolivar
Santo Domingo
1101
Dominican Republic

Phone +1 (0)8094810572
Email jamescollins@pucmm.edu.do

Study information

Study designRandomized parallel placebo-controlled double-blinded clinical trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet No participant information sheet available
Scientific titleAdjunctive efficacy of systemic metronidazole in the surgical treatment of periodontitis: a randomized placebo-controlled clinical trial
Study objectivesTo determine whether the use of a systemic antimicrobial (metronidazole), as an adjunctive treatment to periodontal surgery (step 3), provides additional clinical and microbiological benefits, in patients with severe generalised chronic periodontitis (generalised stages III-IV, grades B-C periodontitis).
Ethics approval(s)Approved 12/03/2015, Ethical Committee of the Faculty of Health (COBE) of the Pontificia Universidad Católica Madre y Maestra (PUCMM) (Autopista Duarte Km 1 1/2, Santiago, República Dominicana; +1 (809) 580-1962, ext. 4416; brodriguez@pucmm.edu.do), ref: COBE-FACS-EXT-003-1-2014-2015
Health condition(s) or problem(s) studiedSevere generalised chronic periodontitis (generalised stages III-IV, grades B-C periodontitis)
InterventionParticipants are randomly assigned to treatment groups in ascending order, at the time of surgery, according to a balanced distribution system (random block design, block size = 6).
1. Test group: blisters consisted of 500 mg metronidazole, to be taken three times per day for 7 days after the last surgery
2. Placebo group

In the initial evaluation, a clinical examination is carried out to establish the periodontal diagnosis. Clinical measurements include: PD and gingival recession/overgrowth (REC), measured to the nearest millimeter; CAL, calculated as the sum⁄rest of PD and REC; bleeding on probing (BOP), assessed dichotomously. Plaque index (PlI) is also assessed. In each quadrant, the most accessible location with the deepest PD and BOP is selected. Subgingival plaque samples are obtained at the same sites throughout the study at the deepest site of each quadrant. All participants receive motivational sessions on oral hygiene instructions and scaling and root planning. Six weeks after the last session of SRP, the re-evaluation is performed and a new full periodontal examination is performed. Those presenting multiple locations with PD ≥5 mm with BOP in ≥1 quadrant received periodontal surgery through open flap debridment. After the last surgical procedure is performed, the medication is provided to the participants, with the instructions to start with the drug regime, three times a day for 7 days. Clinical parameters are recorded 3 months after the last surgery session, and then after 6 and 12 months. Following the active treatment, at 3, 6, 9 and 12 months all patients receive a full mouth professional mechanical plaque removal (PMPR), including SRP as needed and polishing of all dental surfaces present, in both groups.
Intervention typeMixed
Primary outcome measureProbing Depth (PD), measured using a UNC-15 mm periodontal probe (Hu-Friedy, Leinmen, Germany) at baseline and 12-month visit
Secondary outcome measuresAt baseline, 3 months after the last surgery session, and then after 6 and 12 months:
1. Probing Depth distribution [⁄overgrowth (measured to the nearest millimeter), Clinical Attachment Loss (calculated as the sum⁄rest of PD and REC) and open pockets measured using a UNC-15 mm periodontal probe (Hu-Friedy, Leinmen, Germany)
2. Plaque Index recorded using the O'Leary Index
3. Bleeding on Probing measured using a dichotomous analysis (presence or absence)

4. Microbiological variables (frequency of detection and counts of each targeted bacteria) samples analysed by multiplex quantitative polymerase chain reaction (qPCR), at baseline and after 12 months following surgical therapy
Overall study start date29/04/2014
Completion date15/05/2019

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participantsTwo groups with 25 patients each
Total final enrolment40
Key inclusion criteria1. Severe generalized chronic periodontitis (Armitage, 1999), corresponding to generalized stage III-IV periodontitis, with grades B-C (Caton et al., 2018; Papapanou et al., 2018; Tonetti, Greenwell, & Kornman, 2018)
2. A least 10 teeth in function, excluding third molars
3. Sites with PD> 5 mm, in ≥2 teeth in ≥1 quadrant
4. Radiographic evidence of bone loss ≥30% in, at least, 30% of the dentition
5. Older than 18 years
Key exclusion criteria1. Pregnant or breastfeeding women
2. Systemic diseases and/or chronic medications that may affect the periodontal status and /or requiring antibiotic prophylaxis
3. Having received systemic antimicrobial treatment in the previous 3 months
4. Have received periodontal treatment in the 6 months prior to the start of the study
5. Allergic to metronidazole, or to any of the components of their commercial formulations (Metrex 500 mg®, Laboratorio Union SRL, Santo Domingo, República Dominicana)
6. Refuse to sign the informed consent
7. Smokers ≥10 cigarettes/day
Date of first enrolment10/02/2015
Date of final enrolment15/02/2018

Locations

Countries of recruitment

  • Dominican Republic

Study participating centre

Pontificia Universidad Católica Madre y Maestra (PUCMM-CSD)
Av Abraham Lincoln esq. Simón Bolivar
Santo Domingo
10109
Dominican Republic

Sponsor information

Pontificia Universidad Católica Madre y Maestra
University/education

Av Abraham Lincoln esq. Simón Bolivar
Santo Domingo
10109
Dominican Republic

Phone +1 (0)8095350111 Ext. 2094
Email jeanmybautista@pucmm.edu.do
Website https://www.pucmm.edu.do/

Funders

Funder type

University/education

Pontificia Universidad Católica Madre y Maestra

No information available

Results and Publications

Intention to publish date10/03/2021
Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryAvailable on request
Publication and dissemination planStudy protocol can be available on request. Planned publication in a high-impact peer-reviewed journal.
IPD sharing planNot provided at registration

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article 05/02/2022 14/03/2022 Yes No
Protocol file in Spanish 27/09/2022 No No

Additional files

39073 Protocol.pdf
in Spanish

Editorial Notes

27/09/2022: Uploaded protocol (not peer-reviewed) as an additional file.
14/03/2022: Publication reference added.
03/12/2020: Trial’s existence confirmed by Ethical Committee of the Faculty of Health (COBE) of the Pontificia Universidad Católica Madre y Maestra.